Ocugen (OCGN) Stock: Why It Rose
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $0.79, +0.94% vs the prior close of $0.78.
- Volume 4.46M shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)
OCGN rises 0.9% to $0.79. Closed at $0.79, +0.94% vs the prior close of $0.78. Day range $0.78–$0.81, opened at $0.80.
OCGN daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — OCGN rises 0.9% to $0.79
- Closed at $0.79, +0.94% vs the prior close of $0.78. Day range $0.78–$0.81, opened at $0.80.
- Volume was 4.45M shares, 0.7x its 50-day average of 6.53M.
- Price is -31.2% vs its 50-day average ($1.14) and -46.3% vs its 200-day average ($1.47).
- 52-week range $0.78–$2.72; today's close sits at 0% of that range, 71.1% below the 52-week high.
Oct 16, 2026 — OCGN slides 4.1% to $0.78, a 52-week low, 9 down days in a row
- Closed at $0.78, -4.14% vs the prior close of $0.81. Day range $0.78–$0.84, opened at $0.84.
- Volume was 5.13M shares, 0.8x its 50-day average of 6.54M.
- Price is -32.4% vs its 50-day average ($1.15) and -46.9% vs its 200-day average ($1.47).
- 52-week range $0.78–$2.72; today's close sits at 0% of that range, 71.4% below the 52-week high.
- That makes 9 straight losses.
Oct 15, 2026 — OCGN slides 3.2% to $0.81, a 52-week low, 8 down days in a row
- Closed at $0.81, -3.21% vs the prior close of $0.84. Day range $0.79–$0.85, opened at $0.84.
- Volume was 5.93M shares, 0.9x its 50-day average of 6.54M.
- Price is -30.0% vs its 50-day average ($1.16) and -44.7% vs its 200-day average ($1.47).
- 52-week range $0.79–$2.72; today's close sits at 1% of that range, 70.1% below the 52-week high.
- That makes 8 straight losses.
- SEC filings that day: 8-K, 8-K.
Oct 14, 2026 — OCGN slides 5.0% to $0.84, a 52-week low, 7 down days in a row
- Closed at $0.84, -4.97% vs the prior close of $0.88. Day range $0.79–$0.92, opened at $0.89.
- Volume was 9.53M shares, 1.5x its 50-day average of 6.48M.
- Price is -28.3% vs its 50-day average ($1.17) and -43.0% vs its 200-day average ($1.48).
- 52-week range $0.79–$2.72; today's close sits at 3% of that range, 69.1% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — OCGN slides 6.5% to $0.88, a 52-week low, 6 down days in a row
- Closed at $0.88, -6.55% vs the prior close of $0.95. Day range $0.87–$0.94, opened at $0.94.
- Volume was 6.89M shares, 1.1x its 50-day average of 6.42M.
- Price is -25.1% vs its 50-day average ($1.18) and -40.1% vs its 200-day average ($1.48).
- 52-week range $0.87–$2.72; today's close sits at 1% of that range, 67.5% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — OCGN dips 0.9% to $0.95, a 52-week low, 5 down days in a row
- Closed at $0.95, -0.94% vs the prior close of $0.96. Day range $0.92–$0.98, opened at $0.96.
- Volume was 3.27M shares, 0.5x its 50-day average of 6.43M — lighter than usual.
- Price is -20.4% vs its 50-day average ($1.19) and -36.1% vs its 200-day average ($1.48).
- 52-week range $0.90–$2.72; today's close sits at 3% of that range, 65.2% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — OCGN dips 2.1% to $0.96, a 52-week low on 2.1x normal volume
- Closed at $0.96, -2.15% vs the prior close of $0.98. Day range $0.90–$1.00, opened at $0.97.
- Volume was 13.34M shares, 2.1x its 50-day average of 6.24M — unusually heavy trading.
- Price is -20.0% vs its 50-day average ($1.19) and -35.6% vs its 200-day average ($1.48).
- 52-week range $0.90–$2.72; today's close sits at 3% of that range, 64.9% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — OCGN dips 2.3% to $0.98, a 52-week low on 2.0x normal volume
- Closed at $0.98, -2.30% vs the prior close of $1.00. Day range $0.96–$1.01, opened at $1.01.
- Volume was 12.02M shares, 2.0x its 50-day average of 6.14M — unusually heavy trading.
- Price is -18.7% vs its 50-day average ($1.20) and -34.3% vs its 200-day average ($1.49).
- 52-week range $0.96–$2.72; today's close sits at 1% of that range, 64.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — OCGN slides 3.8% to $1.00
- Closed at $1.00, -3.85% vs the prior close of $1.04. Day range $1.00–$1.05, opened at $1.04.
- Volume was 5.22M shares, 0.9x its 50-day average of 6.13M.
- Price is -17.0% vs its 50-day average ($1.21) and -32.8% vs its 200-day average ($1.49).
- 52-week range $0.97–$2.72; today's close sits at 2% of that range, 63.3% below the 52-week high.
Oct 6, 2026 — OCGN ends flat (+0.0%) to $1.04
- Closed at $1.04, +0.00% vs the prior close of $1.04. Day range $1.04–$1.12, opened at $1.05.
- Volume was 5.29M shares, 0.9x its 50-day average of 6.12M.
- Price is -14.1% vs its 50-day average ($1.21) and -30.2% vs its 200-day average ($1.49).
- 52-week range $0.97–$2.72; today's close sits at 4% of that range, 61.8% below the 52-week high.
- SEC filings that day: 8-K.
Oct 5, 2026 — OCGN rises 2.0% to $1.04
- Closed at $1.04, +1.96% vs the prior close of $1.02. Day range $1.00–$1.05, opened at $1.03.
- Volume was 5.49M shares, 0.9x its 50-day average of 6.10M.
- Price is -14.4% vs its 50-day average ($1.21) and -30.3% vs its 200-day average ($1.49).
- 52-week range $0.97–$2.72; today's close sits at 4% of that range, 61.8% below the 52-week high.
Oct 2, 2026 — OCGN rises 2.0% to $1.02
- Closed at $1.02, +2.00% vs the prior close of $1.00. Day range $1.01–$1.04, opened at $1.04.
- Volume was 3.45M shares, 0.6x its 50-day average of 6.09M — lighter than usual.
- Price is -16.3% vs its 50-day average ($1.22) and -31.7% vs its 200-day average ($1.49).
- 52-week range $0.97–$2.72; today's close sits at 3% of that range, 62.6% below the 52-week high.
OCGN bull case vs bear case (from the data)
- Annual revenue grew 8.8% in the latest fiscal year (SEC XBRL).
- Insiders made 4 open-market purchases in the last 12 months.
- Price is -31.2% vs its 50-day average — short-term trend is down.
- Price is -46.3% vs its 200-day average — below the long-term trend line.
- Latest fiscal-year net income: loss of $67.85M.
- Insider selling outweighs buying: 8 sales vs 4 open-market buys among the 12 most recent reported insider trades (Form 4, last 12 months).
- Share count up 16.0% in a year (dilution).
OCGN latest news & SEC filings
Every SEC filing by or about OCGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Musunuri Shankar sold 468,727 shares at $0.95 (≈$445.29K) on Oct 9, 2026; now holds 4,018,470
- Musunuri Shankar sold 57,264 shares at $0.95 (≈$54.40K) on Oct 9, 2026; now holds 1,030,771
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Musunuri Shankar sold 468,727 shares at $1.12 (≈$524.97K) on Sep 9, 2026
- Musunuri Shankar sold 57,264 shares at $1.12 (≈$64.14K) on Sep 9, 2026
- Musunuri Shankar sold 468,727 shares at $1.12 (≈$524.97K) on Sep 9, 2026
- Musunuri Shankar sold 57,264 shares at $1.12 (≈$64.14K) on Sep 9, 2026
- Musunuri Shankar sold 468,727 shares at $1.12 (≈$524.97K) on Sep 9, 2026
- Musunuri Shankar sold 57,264 shares at $1.12 (≈$64.14K) on Sep 9, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.49M (prior year $1.37M) (+8.4% vs Jun 30, 2025)
- Net income: -$24.88M (prior year -$14.74M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.07 (prior year -$0.05) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Things to know before you trade OCGN
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, May 5, 2026, May 4, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.75% (largest 6.5%).
- Liquidity: about 6.85M shares (≈$5.39M) trade per day on average.
- 52-week position: $0.79 vs a range of $0.78–$2.72 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 8 sales; latest: Shankar Musunuri sold 468,727 shares on Sep 9, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Oct 15, 2026; 8-K Oct 6, 2026.
- Share count: 339.11M shares outstanding (Jul 31, 2026), +16.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
OCGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 0.80 | 0.81 | 0.78 | 0.79 | 4.46M |
| Oct 16, 2026 | 0.84 | 0.84 | 0.78 | 0.78 | 5.14M |
| Oct 15, 2026 | 0.84 | 0.85 | 0.79 | 0.81 | 5.93M |
| Oct 14, 2026 | 0.89 | 0.92 | 0.79 | 0.84 | 9.53M |
| Oct 13, 2026 | 0.94 | 0.94 | 0.87 | 0.88 | 6.89M |
| Oct 12, 2026 | 0.96 | 0.98 | 0.92 | 0.95 | 3.27M |
| Oct 9, 2026 | 0.97 | 1.00 | 0.90 | 0.96 | 13.34M |
| Oct 8, 2026 | 1.01 | 1.01 | 0.96 | 0.98 | 12.02M |
| Oct 7, 2026 | 1.04 | 1.05 | 1.00 | 1.00 | 5.22M |
| Oct 6, 2026 | 1.05 | 1.12 | 1.04 | 1.04 | 5.29M |
| Oct 5, 2026 | 1.03 | 1.05 | 1.00 | 1.04 | 5.49M |
| Oct 2, 2026 | 1.04 | 1.04 | 1.01 | 1.02 | 3.45M |
| Oct 1, 2026 | 1.03 | 1.05 | 1.00 | 1.00 | 5.06M |
| Sep 30, 2026 | 1.09 | 1.10 | 1.01 | 1.03 | 7.32M |
| Sep 29, 2026 | 1.05 | 1.10 | 1.04 | 1.09 | 7.55M |
| Sep 28, 2026 | 1.02 | 1.05 | 1.00 | 1.03 | 4.86M |
| Sep 25, 2026 | 1.06 | 1.09 | 1.01 | 1.02 | 8.69M |
| Sep 24, 2026 | 1.00 | 1.02 | 0.97 | 1.00 | 5.62M |
| Sep 23, 2026 | 1.06 | 1.06 | 0.98 | 1.00 | 12.16M |
| Sep 22, 2026 | 1.05 | 1.08 | 1.03 | 1.04 | 5.71M |
About Ocugen
Ocugen (OCGN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in MALVERN, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1372299.
OCGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kirsten Castillo | Director | Jun 15, 2026 |
| Satishchandran Chandrasekhar | Director | Jun 15, 2026 |
| Blaise Coleman | Director | Jun 15, 2026 |
| Uday Kompella | Director | Jun 15, 2026 |
| Shankar Musunuri | Chief Executive Officer | Sep 11, 2026 |
| Junge Zhang | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Treerita Essalima Johnson-Greene | Chief Financial Officer | Jun 17, 2026 |
| Shankar Musunuri | Chief Executive Officer | Sep 11, 2026 |
| Ramesh Ramachandran | Chief Accounting Officer | Jan 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Shankar Musunuri | Sale | 468,727 | $1.12 |
| Sep 9, 2026 | Shankar Musunuri | Sale | 57,264 | $1.12 |
| Sep 9, 2026 | Shankar Musunuri | Sale | 468,727 | $1.12 |
| Sep 9, 2026 | Shankar Musunuri | Sale | 57,264 | $1.12 |
| Sep 9, 2026 | Shankar Musunuri | Sale | 468,727 | $1.12 |
| Sep 9, 2026 | Shankar Musunuri | Sale | 57,264 | $1.12 |
| Sep 9, 2026 | Shankar Musunuri | Sale | 468,727 | $1.12 |
| Sep 9, 2026 | Shankar Musunuri | Sale | 57,264 | $1.12 |
| Jun 15, 2026 | Treerita Essalima Johnson-Greene | Buy | 21,000 | $1.23 |
| Jun 15, 2026 | Treerita Essalima Johnson-Greene | Buy | 21,000 | $1.23 |
| Jun 15, 2026 | Treerita Essalima Johnson-Greene | Buy | 21,000 | $1.23 |
| Jun 15, 2026 | Treerita Essalima Johnson-Greene | Buy | 21,000 | $1.23 |
OCGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $4.41M | $-67.85M | — | $-56.96M |
| Dec 31, 2024 | $4.05M | $-54.05M | — | $-42.14M |
| Dec 31, 2023 | $6.04M | $-63.08M | -0.26 | $-62.05M |
| Dec 31, 2022 | $2.49M | $-86.80M | -0.40 | $-60.08M |
| Dec 31, 2021 | — | $-58.37M | -0.30 | $-47.94M |
Latest balance sheet: total assets $124.21M, total liabilities $140.76M, cash $100.05M (as of Jun 30, 2026).
OCGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $1.24 |
| May 7, 2026 | 8-K Item 2.02 (results) | $1.44 |
| May 5, 2026 | 8-K Item 2.02 (results) | $1.49 |
| May 4, 2026 | 8-K Item 2.02 (results) | $1.85 |
| Mar 4, 2026 | 8-K Item 2.02 (results) | $1.96 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $1.41 |
| Aug 1, 2025 | 8-K Item 2.02 (results) | $0.99 |
| May 9, 2025 | 8-K Item 2.02 (results) | $0.67 |
| Mar 5, 2025 | 8-K Item 2.02 (results) | $0.57 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $0.99 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Tesla (TSLA)Space Exploration Technologies (SPCX)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on OCGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.